Because lobular carcinoma resists neoadjuvant therapy (18), the survival rate of patients with these tumors is lower than that of ductal carcinoma patients (19, 20), and these data may suggest that EMP1 has the function of promoting tumor progression. This evidence concerns the gene EMP1 and breast lobular carcinoma.